177Lu-PNT2002 (formerly 177Lu-PSMA-I&T is a peptide developed by the Technical University Munich and Scintomics. It was labeled also with 68Ga and 111In for respectively PET and SPECT Imaging (but also radio-guided surgery), hence creating a PSMA-probes platform. This drug is an alternative to 177Lu-PSMA-617. The US company Point Biopharma acquired the rights for this molecule and initiated a Phase III trial in December 2020 with funding from Research Alliance Corp. The drug could reach the market by end of 2023 or 2024.

Target/Mechanism: PSMA

Leading Emitter: beta electrons (β)